Endometrial stromal sarcomas: A review of potential prognostic factors

Advances in Anatomic Pathology

Volumn 17, Issue 2, 2010, Pages 113-121

  Chew, Ivy ^a   Oliva, Esther ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Endometrial stromal nodule; Endometrial stromal sarcoma; Prognostic factors; Undifferentiated endometrial sarcoma

Indexed keywords

CANCER SURGERY; CANCER SURVIVAL; DNA DETERMINATION; ENDOMETRIUM SARCOMA; HUMAN; MENOPAUSE; MITOSIS INDEX; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUMOR VOLUME; WORLD HEALTH ORGANIZATION;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PARITY; PREGNANCY; PROGNOSIS; SARCOMA, ENDOMETRIAL STROMAL; UTERINE NEOPLASMS; UTERUS;

EID: 77649157375     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0b013e3181cfb7c2     Document Type: Review

References (103)

1. Moinfar F, Kremser ML, Man YG, et al. Allelic imbalances in endometrial stromal neoplasms: frequent genetic alterations in the nontumorous normal-appearing endometrial and myometrial tissues. Gynecol Oncol. 2004;95:662-671.
2. Norris HJ, Taylor HB. Mesenchymal tumors of the uterus. I. A clinical and pathological study of 53 endometrial stromal tumors. Cancer. 1966;19:755-766.
3. Hendrickson MR, Tavassoli FA, Kempson RL, et al. Mesenchymal tumours and related lesions. In: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon, France: IARC Press; 2003.
4. Dionigi A, Oliva E, Clement PB, et al. Endometrial stromal nodules and endometrial stromal tumors with limited infiltration: a clinicopathologic study of 50 cases. Am J Surg Pathol. 2002;26:567-581.
5. Tavassoli FA, Norris HJ. Mesenchymal tumours of the uterus. VII. A clinicopathological study of 60 endometrial stromal nodules. Histopathology. 1981;5:1-10.
6. Oliva E, Clement PB, Young RH. Endometrial stromal tumors: an update on a group of tumors with a protean phenotype. Adv Anat Pathol. 2000;7:257-281.
7. Chang KL, Crabtree GS, Lim-Tan SK, et al. Primary uterine endometrial stromal neoplasms. A clinicopathologic study of 117 cases. Am J Surg Pathol. 1990;14:415-438.
8. Oliva E, Clement PB, Young RH, et al. Mixed endometrial stromal and smooth muscle tumors of the uterus: a clinicopathologic study of 15 cases. Am J Surg Pathol. 1998;22: 997-1005.
9. Baker P, Oliva E. Endometrial stromal tumours of the uterus: a practical approach using conventional morphology and ancillary techniques. J Clin Pathol. 2007;60: 235-243.
10. Schilder JM, Hurd WW, Roth LM, et al. Hormonal treatment of an endometrial stromal nodule followed by local excision. Obstet Gynecol. 1999;93:805-807.
11. Vilos GA, Harding PG, Sugimoto AK, et al. Hysteroscopic endomyometrial resection of three uterine sarcomas. J Am Assoc Gynecol Laparosc. 2001;8:545-551.
12. Evans HL. Endometrial stromal sarcoma and poorly differentiated endometrial sarcoma. Cancer. 1982;50:2170-2182.
13. Stadsvold JL, Molpus KL, Baker JJ, et al. Conservative management of a myxoid endometrial stromal sarcoma in a 16-year-old nulliparous woman. Gynecol Oncol. 2005;99: 243-245.
14. Chan JK, Kawar NM, Shin JY, et al. Endometrial stromal sarcoma: a population-based analysis. Br J Cancer. 2008;99: 1210-1215.
15. Hart WR, Yoonessi M. Endometrial stromatosis of the uterus. Obstet Gynecol. 1977;49:393-403.
16. Young RH, Scully RE. Sarcomas metastatic to the ovary: a report of 21 cases. Int J Gynecol Pathol. 1990;9:231-252.
17. Young RH, Prat J, Scully RE. Endometrioid stromal sarcomas of the ovary. A clinicopathologic analysis of 23 cases. Cancer. 1984;53:1143-1155.
18. Aubry MC, Myers JL, Colby TV, et al. Endometrial stromal sarcoma metastatic to the lung: a detailed analysis of 16 patients. Am J Surg Pathol. 2002;26:440-449.
19. Fekete PS, Vellios F. The clinical and histologic spectrum of endometrial stromal neoplasms: a report of 41 cases. Int J Gynecol Pathol. 1984;3:198-212.
20. Leath CA III, Huh WK, Hyde J Jr, et al. A multi-institutional review of outcomes of endometrial stromal sarcoma. Gynecol Oncol. 2007;105:630-634.
21. Beer TW, Buchanan R, Buckley CH. Uterine stromal sarcoma following tamoxifen treatment. J Clin Pathol. 1995; 48:596.
22. Meredith RF, Eisert DR, Kaka Z, et al. An excess of uterine sarcomas after pelvic irradiation. Cancer. 1986;58:2003-2007.
23. Yoonessi M, Hart WR. Endometrial stromal sarcomas. Cancer. 1977;40:898-906.
24. Yilmaz A, Rush DS, Soslow RA. Endometrial stromal sarcomas with unusual histologic features: a report of 24 primary and metastatic tumors emphasizing fibroblastic and smooth muscle differentiation. Am J Surg Pathol. 2002;26: 1142-1150.
25. Schammel DP, Silver SA, Tavassoli FA. Combined endometrial stromal/smooth muscle neoplasms of the uterus. A clinicopathologic study of 38 cases [abstract]. Mod Pathol. 1999;12:124A.
26. Oliva E, Young RH, Clement PB, et al. Myxoid and fibrous endometrial stromal tumors of the uterus: a report of 10 cases. Int J Gynecol Pathol. 1999;18:310-319.
27. Kasashima S, Kobayashi M, Yamada M, et al. Myxoid endometrial stromal sarcoma of the uterus. Pathol Int. 2003; 53:637-641.
28. Clement PB, Scully RE. Uterine tumors resembling ovarian sex-cord tumors. A clinicopathologic analysis of fourteen cases. Am J Clin Pathol. 1976;66:512-525.
29. McCluggage WG, Date A, Bharucha H, et al. Endometrial stromal sarcoma with sex cord-like areas and focal rhabdoid differentiation. Histopathology. 1996;29:369-374.
30. Zamecnik M, Michal M. Endometrial stromal nodule with retiform sex-cord-like differentiation. Pathol Res Pract. 1998; 194:449-453.
31. Clement PB, Scully RE. Endometrial stromal sarcomas of the uterus with extensive endometrioid glandular differentiation: a report of three cases that caused problems in differential diagnosis. Int J Gynecol Pathol. 1992;11:163-173.
32. McCluggage WG, Cromie AJ, Bryson C, et al. Uterine endometrial stromal sarcoma with smooth muscle and glandular differentiation. J Clin Pathol. 2001;54:481-483.
33. Oliva E, Clement PB, Young RH. Epithelioid endometrial and endometrioid stromal tumors: a report of four cases emphasizing their distinction from epithelioid smooth muscle tumors and other oxyphilic uterine and extrauterine tumors. Int J Gynecol Pathol. 2002;21:48-55.
34. Lifschitz-Mercer B, Czernobilsky B, Dgani R, et al. Immunocytochemical study of an endometrial diffuse clear cell stromal sarcoma and other endometrial stromal sarcomas. Cancer. 1987;59:1494-1499.
35. Tanimoto A, Sasaguri T, Arima N, et al. Endometrial stromal sarcoma of the uterus with rhabdoid features. Pathol Int. 1996;46:231-237.
36. Kim YH, Cho H, Kyeom-Kim H, et al. Uterine endometrial stromal sarcoma with rhabdoid and smooth muscle differentiation. J Korean Med Sci. 1996;11:88-93.
37. Baker PM, Moch H, Oliva E. Unusual morphologic features of endometrial stromal tumors: a report of 2 cases. Am J Surg Pathol. 2005;29:1394-1398.
38. Lloreta J, Prat J. Endometrial stromal nodule with smooth and skeletal muscle components simulating stromal sarcoma. Int J Gynecol Pathol. 1992;11:293-298.
39. Farhood AI, Abrams J. Immunohistochemistry of endometrial stromal sarcoma. Hum Pathol. 1991;22:224-230.
40. Abrams J, Talcott J, Corson JM. Pulmonary metastases in patients with low-grade endometrial stromal sarcoma. Clinicopathologic findings with immunohistochemical characterization. Am J Surg Pathol. 1989;13:133-140.
41. Oliva E, Young RH, Amin MB, et al. An immunohistochemical analysis of endometrial stromal and smooth muscle tumors of the uterus: a study of 54 cases emphasizing the importance of using a panel because of overlap in immunoreactivity for individual antibodies. Am J Surg Pathol. 2002; 26:403-412.
42. Franquemont DW, Frierson HF Jr, Mills SE. An immunohistochemical study of normal endometrial stroma and endometrial stromal neoplasms. Evidence for smooth muscle differentiation. Am J Surg Pathol. 1991;15:861-870.
43. Devaney K, Tavassoli FA. Immunohistochemistry as a diagnostic aid in the interpretation of unusual mesenchymal tumors of the uterus. Mod Pathol. 1991;4:225-231.
44. Lillemoe TJ, Perrone T, Norris HJ, et al. Myogenous phenotype of epithelial-like areas in endometrial stromal sarcomas. Arch Pathol Lab Med. 1991;115:215-219.
45. Jung CK, Jung JH, Lee A, et al. Diagnostic use of nuclear beta-catenin expression for the assessment of endometrial stromal tumors. Mod Pathol. 2008;21:756-763.
46. Ng TL, Gown AM, Barry TS, et al. Nuclear beta-catenin in mesenchymal tumors. Mod Pathol. 2005;18:68-74.
47. Kurihara S, Oda Y, Ohishi Y, et al. Coincident expression of beta-catenin and cyclin D1 in endometrial stromal tumors and related high-grade sarcomas. Mod Pathol. 2009. [Epub ahead of print].
48. Chu P, Arber DA. Paraffin-section detection of CD10 in 505 nonhematopoietic neoplasms. Frequent expression in renal cell carcinoma and endometrial stromal sarcoma. Am J Clin Pathol. 2000;113:374-382.
49. McCluggage WG, Sumathi VP, Maxwell P. CD10 is a sensitive and diagnostically useful immunohistochemical marker of normal endometrial stroma and of endometrial stromal neoplasms. Histopathology. 2001;39:273-278.
50. Chu PG, Arber DA, Weiss LM, et al. Utility of CD10 in distinguishing between endometrial stromal sarcoma and uterine smooth muscle tumors: an immunohistochemical comparison of 34 cases. Mod Pathol. 2001;14:465-471.
51. Mikami Y, Hata S, Kiyokawa T, et al. Expression of CD10 in malignant Mullerian mixed tumors and adenosarcomas: an immunohistochemical study. Mod Pathol. 2002;15:923-930.
52. Oliva E. CD10 expression in the female genital tract: does it have useful diagnostic applications? Adv Anat Pathol. 2004; 11:310-315.
53. Zhu XQ, Shi YF, Cheng XD, et al. Immunohistochemical markers in differential diagnosis of endometrial stromal sarcoma and cellular leiomyoma. Gynecol Oncol. 2004;92: 71-79.
54. Nucci MR, O'Connell JT, Huettner PC, et al. h-Caldesmon expression effectively distinguishes endometrial stromal tumors from uterine smooth muscle tumors. Am J Surg Pathol. 2001;25:455-463.
55. Rush DS, Tan J, Baergen RN, et al. h-Caldesmon, a novel smooth muscle-specific antibody, distinguishes between cellular leiomyoma and endometrial stromal sarcoma. Am J Surg Pathol. 2001;25:253-258.
56. de Leval L, Waltregny D, Boniver J, et al. Use of histone deacetylase 8 (HDAC8), a new marker of smooth muscle differentiation, in the classification of mesenchymal tumors of the uterus. Am J Surg Pathol. 2006;30:319-327.
57. Loo KT, Leung AK, Chan JK. Immunohistochemical staining of ovarian granulosa cell tumours with MIC2 antibody. Histopathology. 1995;27:388-390.
58. Baker RJ, Hildebrandt RH, Rouse RV, et al. Inhibin and CD99 (MIC2) expression in uterine stromal neoplasms with sex-cord-like elements. Hum Pathol. 1999;30:671-679.
59. Irving JA, Carinelli S, Prat J. Uterine tumors resembling ovarian sex cord tumors are polyphenotypic neoplasms with true sex cord differentiation. Mod Pathol. 2006;19:17-24.
60. Reich O, Regauer S. Hormonal therapy of endometrial stromal sarcoma. Curr Opin Oncol. 2007;19:347-352.
61. Gadducci A, Cosio S, Romanini A, et al. The management of patients with uterine sarcoma: a debated clinical challenge. Crit Rev Oncol Hematol. 2008;65:129-142.
62. Silverberg SG, Kurman RJ. Endometrial stromal tumors. In: Silverberg SG, Kurman RJ, eds. Atlas of Tumor Pathology Tumors of the Uterine Corpus and Gestational Trophoblastic Disease Third Series, Fascicle 3. Washington, DC: Armed Forces Institute of Pathology; 1992:91-111.
63. Amant F, Woestenborghs H, Vandenbroucke V, et al. Transition of endometrial stromal sarcoma into high-grade sarcoma. Gynecol Oncol. 2006;103:1137-1140.
64. Cheung AN, Ng WF, Chung LP, et al. Mixed low grade and high grade endometrial stromal sarcoma of uterus: differences on immunohistochemistry and chromosome in situ hybridisation. J Clin Pathol. 1996;49:604-607.
65. Malpica A, Deavers MT, Silva EG. High grade sarcoma in endometrial stromal sarcoma: dedifferentiated endometrial stromal sarcoma [abstract]. Mod Pathol. 2006;19:188A.
66. Abeler VM, Royne O, Thoresen S, et al. Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology. 2009;54:355-364.
67. Denschlag D, Masoud I, Stanimir G, et al. Prognostic factors and outcome in women with uterine sarcoma. Eur J Surg Oncol. 2007;33:91-95.
68. Kurihara S, Oda Y, Ohishi Y, et al. Endometrial stromal sarcomas and related high-grade sarcomas: immunohistochemical and molecular genetic study of 31 cases. Am J Surg Pathol. 2008;32:1228-1238.
69. D'Angelo E, Spagnoli LG, Prat J. Comparative clinicopathologic and immunohistochemical analysis of uterine sarcomas diagnosed using the World Health Organization classification system. Hum Pathol. 2009;40:1571-1585.
70. Bodner K, Bodner-Adler B, Obermair A, et al. Prognostic parameters in endometrial stromal sarcoma: a clinicopathologic study in 31 patients. Gynecol Oncol. 2001;81:160-165.
71. De Nictolis M, Curatola A, Tommasoni S, et al. High-grade endometrial stromal sarcoma: clinicopathologic and immunohistochemical study of a case. Pathologica. 1994;86: 217-221.
72. Kim WY, Lee J-W, Choi CH, et al. Low-grade endometrial stromal sarcoma: a single center's experience with 22 cases. Int J Gynecol Cancer. 2008;18:1084-1089.
73. Dunton CJ, Kelsten ML, Brooks SE, et al. Low-grade stromal sarcoma: DNA flow cytometric analysis and estrogen progesterone receptor data. Gynecol Oncol. 1990;37: 268-275.
74. Haberal A, Kayikcioglu F, Boran N, et al. Endometrial stromal sarcoma of the uterus: analysis of 25 patients. Eur J Obstet Gynecol Reprod Biol. 2003;109:209-213.
75. Chu MC, Mor G, Lim C, et al. Low-grade endometrial stromal sarcoma: hormonal aspects. Gynecol Oncol. 2003;90: 170-176.
76. el-Naggar AK, Abdul-Karim FW, Silva EG, et al. Uterine stromal neoplasms: a clinicopathologic and DNA flow cytometric correlation. Hum Pathol. 1991;22:897-903.
77. Blom R, Malmstrom H, Guerrieri C. Endometrial stromal sarcoma of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 17 cases. Int J Gynecol Cancer. 1999;9:98-104. (Pubitemid 29220745)
78. Nola M, Babic D, Ilic J, et al. Prognostic parameters for survival of patients with malignant mesenchymal tumors of the uterus. Cancer. 1996;78:2543-2550.
79. Nordal RR, Kristensen GB, Kaern J, et al. The prognostic significance of surgery, tumor size, malignancy grade, menopausal status, and DNA ploidy in endometrial stromal sarcoma. Gynecol Oncol. 1996;62:254-259.
80. Kildal W, Abeler VM, Kristensen GB, et al. The prognostic value of DNA ploidy in a total population of uterine sarcomas. Ann Oncol. 2009;20:1037-1041.
81. Akahira J, Tokunaga H, Toyoshima M, et al. Prognoses and prognostic factors of carcinosarcoma, endometrial stromal sarcoma and uterine leiomyosarcoma: a comparison with uterine endometrial adenocarcinoma. Oncology. 2006;71: 333-340.
82. Kokawa K, Nishiyama K, Ikeuchi M, et al. Clinical outcomes of uterine sarcomas: results from 14 years worth of experience in the Kinki district in Japan (1990-2003). Int J Gynecol Cancer. 2006;16:1358-1363.
83. Brooks SE, Zhan M, Cote T, et al. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gynecol Oncol. 2004;93:204-208.
84. Albrektsen G, Heuch I, Wik E, et al. Prognostic impact of parity in 493 uterine sarcoma patients. Int J Gynecol Cancer. 2009;19:1062-1067.
85. Koivisto-Korander R, Butzow R, Koivisto A, et al. Clinical outcome and prognostic factors in 100 cases of uterine sarcoma: experience in Helsinki University Central Hospital 1990-2001. Gynecol Oncol. 2008;111:7-81.
86. Chauveinc L, Deniaud E, Plancher C, et al. Uterine sarcomas: the Curie Institute experience. Prognosis factors and adjuvant treatments. Gynecol Oncol. 1999;72:232-237.
87. Park JY, Kim DY, Suh DS, et al. Prognostic factors and treatment outcomes of patients with uterine sarcoma: analysis of 127 patients at a single institution, 1989-2007. J Cancer Res Clin Oncol. 2008;134:1277-1287.
88. El Husseiny G, Al Bareedy N, Mourad WA, et al. Prognostic factors and treatment modalities in uterine sarcoma. Am J Clin Oncol. 2002;25:256-260.
89. De Fusco PA, Gaffey TA, Malkasian GD Jr, et al. Endometrial stromal sarcoma: review of Mayo Clinic experience, 1945-1980. Gynecol Oncol. 1989;35:8-14.
90. Kahanpaa KV, Wahlstrom T, Grohn P, et al. Sarcomas of the uterus: a clinicopathologic study of 119 patients. Obstet Gynecol. 1986;67:417-424.
91. Rovirosa A, Ascaso C, Ordi J, et al. Is vascular and lymphatic space invasion a main prognostic factor in uterine neoplasms with a sarcomatous component? A retrospective study of prognostic factors of 60 patients stratified by stages. Int J Radiat Oncol Biol Phys. 2002;52:1320-1329.
92. Wolfson AH, Wolfson DJ, Sittler SY, et al. A multivariate analysis of clinicopathologic factors for predicting outcome in uterine sarcomas. Gynecol Oncol. 1994;52:56-62.
93. Sagae S, Yamashita K, Ishioka S, et al. Preoperative diagnosis and treatment results in 106 patients with uterine sarcoma in Hokkaido, Japan. Oncology. 2004;67:33-39.
94. Benoit L, Arnould L, Cheynel N, et al. The role of surgery and treatment trends in uterine sarcoma. Eur J Surg Oncol. 2005;31:434-442.
95. August CZ, Bauer KD, Lurain J, et al. Neoplasms of endometrial stroma: histopathologic and flow cytometric analysis with clinical correlation. Hum Pathol. 1989;20: 232-237.
96. Moinfar F, Regitnig P, Tabrizi AD, et al. Expression of androgen receptors in benign and malignant endometrial stromal neoplasms. Virchows Arch. 2004;444:410-414.
97. Reich O, Regauer S, Urdl W, et al. Expression of oestrogen and progesterone receptors in low-grade endometrial stromal sarcomas. Br J Cancer. 2000;82:1030-1034.
98. Ioffe YJ, Li AJ, Walsh CS, et al. Hormone receptor expression in uterine sarcomas: prognostic and therapeutic roles. Gynecol Oncol. 2009;115:466-471.
99. Kitaoka Y, Kitawaki J, Koshiba H, et al. Aromatase cytochrome P450 and estrogen and progesterone receptors in uterine sarcomas: correlation with clinical parameters. J Steroid Biochem Mol Biol. 2004;88:183-189.
100. Balleine RL, Earls PJ, Webster LR, et al. Expression of progesterone receptor A and B isoforms in low-grade endometrial stromal sarcoma. Int J Gynecol Pathol. 2004;23: 138-144.
101. Reich O, Regauer S. Aromatase expression in low-grade endometrial stromal sarcomas: an immunohistochemical study. Mod Pathol. 2004;17:104-108.
102. Emons G, Grundker C, Gunthert AR, et al. GnRH antagonists in the treatment of gynecological and breast cancers. Endocr Relat Cancer. 2003;10:291-299.
103. Reich O, Nogales FF, Regauer S. Gonadotropin-releasing hormone receptor expression in endometrial stromal sarcomas: an immunohistochemical study. Mod Pathol. 2005; 18:573-576.